Lyell Immunopharma (LYEL) Total Current Liabilities (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Total Current Liabilities data on file, last reported at $36.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 10.51% year-over-year to $36.9 million; the trailing twelve-month figure through Mar 2026 stood at $36.9 million (down 10.51% YoY), and the FY2025 full-year result was $49.4 million, down 8.14% from the prior year.
• Total Current Liabilities fell to $36.9 million in Q1 2026, from $49.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $53.8 million in Q4 2024 to a low of $30.8 million in Q1 2023.
• A 5-year average of $38.9 million and a median of $36.9 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities sank 31.62% in 2023 and jumped 55.82% in 2024, its largest moves.
• Tracing LYEL's Total Current Liabilities over 5 years: stood at $37.0 million in 2022, then slipped by 6.78% to $34.5 million in 2023, then soared by 55.82% to $53.8 million in 2024, then dropped by 8.14% to $49.4 million in 2025, then fell by 25.23% to $36.9 million in 2026.
• Business Quant data shows LYEL's Total Current Liabilities at $36.9 million in Q1 2026, $49.4 million in Q4 2025, and $31.9 million in Q3 2025.